CyBorD regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:Bortezomib/Cyclophosphamide/Dexamethasone Regimen; CyBorD; VCD; Velcade-Cyclophosphamide-Dexamethasone
Overview
CyBorD regimen refers to a treatment regimen consisting of a combination of cyclophosphamide, bortezomib (Velcade) and dexamethasone three-drug induction regimen for untreated transplant-eligible multiple myeloma patients[1] and AL amyloidosis[2]
Regimen
CyCyclophosphamide
BorBortezomib (Velcade)
DDexamethasone
Indications
References
- ↑ 1.0 1.1 Areethamsirikul N, Masih-Khan E, Chu CM, Jimenez-Zepeda V, Reece DE, Trudel S; et al. (2015). “CyBorD induction therapy in clinical practice”. Bone Marrow Transplant. 50 (3): 375–9. doi:10.1038/bmt.2014.288. PMID 25599165.
- ↑ 2.0 2.1 Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB; et al. (2012). “Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis”. Blood. 119 (19): 4391–4. doi:10.1182/blood-2011-11-390930. PMC 3557400. PMID 22331188.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH